EsoCap AG

EsoCap AG, a Swiss privately funded Biotech company, developed a novel solution designed to provide targeted and long-lasting local Esophagus therapy.

[EsoCap AG @EsoCapAG]

Thrilled to be presenting at the 32. #MedTech Investing Europe Forum in Lausanne, Switzerland, July 12, 2022!
We’ll discuss how we aim to improve treatment efficiency for esophageal conditions, affecting 370+ M patients p.a. worldwide!
#esophagus #presentation #conference

[EsoCap AG @EsoCapAG]

A big thank you to @Medicine_maker for featuring our CEO, Isabelle Racamier in its upcoming issue.
Great opportunity to highlight the esophageal disease challenges and how #EsoCap is innovating localized #esophagus treatment.
Read the full interview here: https://t.co/RYIzGXQLRj

[EsoCap AG @EsoCapAG]

@WibloCh: Roughly 370 million people a year worldwide suffer from esophageal conditions without any locally administered treatment options. We hope to change that with the first ever targeted, long-lasting #Esophagus #therapy. Read more at https://t.co/uCtInEK0CV

[EsoCap AG @EsoCapAG]

Roughly 370 million people a year worldwide suffer from esophageal conditions without any locally administered treatment options. We hope to change that with the first ever targeted, long-lasting #Esophagus #therapy. Read more at https://t.co/uCtInEK0CV